At 21.6%+ CAGR, Automated Breast Ultrasound Systems Market – The Future of Breast Screening will surpass US$ 1,591.7 Million by 2026 | Hitachi Aloka Medical, Ltd., Koninklijke Philips N.V.

A new report by published by Coherent Market Insights. Increasing incidence of breast cancer is propelling market growth for automated breast ultrasound systems worldwide.Advancements in automated breast ultrasound systems (ABUS) has propelled demand for handheld ultrasound system (HHUS), which is expected to drive market growth over the forecast period.

Recent past has witnessed high demand for ABUS from physician to improve efficiency of diagnosis, owing to various features offered by ABUS such as high quality 3D images, reduced screening time, and the ability to screen dense breast tissues and small tumors effectively.

Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/78
In 2014, the U.S. Food and Drug Administration (FDA) approved GE’s Invenia ABUS for using it as a supplementary product with mammogram in breast cancer diagnosis, which has increased the adoption of ABUS among hospitals for screening of breasts cancer. Furthermore, high prevalence of breast cancer is a major factor driving growth of the market.

According to the American Cancer Society, in 2016, an estimated 246,660 new cases of invasive breast cancer were reported in the U.S. As per the estimates of the Philippine Obstetrical and Gynecological Society, the highest incidence of breast cancers were reported in Philippines, with a mammoth increase of 589% in breast cancer cases reported over a period of 30-years (1980 - 2010).

Furthermore, high adoption of ABUS is accelerating preoperative evaluation of tumors. Various studies are being conducted to establish the benefits of using ABUS in preoperative application. In January 2016, a trial was conducted by the University of Zurich for preoperative evaluation of breast cancer using ABUS in women newly diagnosed with breast cancer. Favorable outcomes of such studies are expected to further expand the scope for ABUS in preoperative evaluation, which in turn is expected to drive growth of the market.

ABUS is majorly adopted in developed economies such as the U.S., Australia, Japan, the U.K., and Canada. However, high costs of installing ABUS and low number of women opting for early breast screening is restraining growth of the market in emerging economies.

Ask Questions to Expertise @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/78

High prevalence of breast cancer and awareness campaigns driving demand for ABUS in developed countries

Factors attributable to the growth of ABUS in North America and European markets include increased patient awareness, high uptake of early breast screening, and availability of funds to install relatively expensive ABUS. According to the World Health Organization (WHO), 232,924 new cases of breast cancer were diagnosed in 2013. Moreover, the American Cancer Society estimates that until 2016 there are over 2.8 million breast cancer survivors in the U.S.

According to the Cancer Research UK, the incidence rate of breast cancer in the U.K is expected to rise by 2% from 2014 to 2035. Public Health England launched a campaign called ‘Be Clear on Cancer’ (2015) to raise breast cancer awareness among women over 70 years. Moreover, research and development in the field is encouraged through the Breast Cancer Now Catalyst Programme (2016).

Detailed Segmentation:
Global Automated Breast Ultrasound Systems Market, By Product Type:
Prone -Type
Supine - Type
Global Automated Breast Ultrasound Systems Market, By End-Use:
Hospitals
Ambulatory Surgical Units
Diagnostic Center
Global Automated Breast Ultrasound Systems Market, By Application (Usage (%), 2015):
Screening
Pre-operative Evaluation

Get Discount @ https://www.coherentmarketinsights.com/insight/request-discount/78

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.